Royal Bank of Canada’s Palvella Therapeutics PVLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16K | Sell |
128
-2,169
| -94% | -$226K | ﹤0.01% | 6000 |
|
|
2025
Q4 | $240K | Sell |
2,297
-483
| -17% | -$41.2K | ﹤0.01% | 4656 |
|
|
2025
Q3 | $174K | Buy |
2,780
+2,743
| +7,414% | +$122K | ﹤0.01% | 5172 |
|
|
2025
Q2 | $1K | Buy |
37
+35
| +1,750% | +$822 | ﹤0.01% | 6966 |
|
|
2025
Q1 | $0 | Buy |
+2
| New | +$39 | ﹤0.01% | 7347 |
|
|
2024
Q3 | – | Sell |
-4
| Closed | – | – | 7602 |
|
|
2024
Q2 | $0 | Buy |
4
+1
| +33% | +$11 | ﹤0.01% | 7642 |
|
|
2024
Q1 | $0 | Sell |
3
-4
| -57% | -$56 | ﹤0.01% | 7718 |
|
|
2023
Q4 | $0 | Sell |
7
-32
| -82% | -$586 | ﹤0.01% | 7685 |
|
|
2023
Q3 | $1K | Buy |
39
+8
| +26% | +$172 | ﹤0.01% | 6967 |
|
|
2023
Q2 | $0 | Buy |
+31
| New | +$1.88K | ﹤0.01% | 7742 |
|
|
2022
Q4 | – | Sell |
-3
| Closed | – | – | 7824 |
|
|
2022
Q3 | $0 | Buy |
3
+2
| +200% | +$258 | ﹤0.01% | 7965 |
|
|
2022
Q2 | $0 | Buy |
+1
| New | +$182 | ﹤0.01% | 7800 |
|
|
2022
Q1 | – | Sell |
-16
| Closed | -$5K | – | 8097 |
|
|
2021
Q4 | $5K | Buy |
+16
| New | +$5.12K | ﹤0.01% | 7231 |
|
|
2021
Q3 | – | Sell |
-162
| Closed | -$50K | – | 7926 |
|
|
2021
Q2 | $50K | Buy |
162
+112
| +224% | +$24.6K | ﹤0.01% | 6046 |
|
|
2021
Q1 | $10K | Sell |
50
-6
| -11% | -$1.31K | ﹤0.01% | 6819 |
|
|
2020
Q4 | $11K | Buy |
+56
| New | +$11.6K | ﹤0.01% | 6341 |
|
|
2020
Q3 | – | Sell |
-28
| Closed | -$6.38K | – | 6988 |
|
|
2020
Q2 | $7K | Buy |
28
+11
| +65% | +$2.57K | ﹤0.01% | 5961 |
|
|
2020
Q1 | $3K | Buy |
+17
| New | +$4.28K | ﹤0.01% | 6225 |
|
|
2019
Q3 | – | Sell |
-33
| Closed | -$12K | – | 7215 |
|
|
2019
Q2 | $12K | Buy |
+33
| New | +$9.84K | ﹤0.01% | 5976 |
|
|
2018
Q4 | – | Sell |
-13
| Closed | -$6K | – | 7183 |
|
|
2018
Q3 | $6K | Buy |
13
+11
| +550% | +$4.78K | ﹤0.01% | 6211 |
|
|
2018
Q2 | $1K | Buy |
+2
| New | +$952 | ﹤0.01% | 6404 |
|
|
2018
Q1 | – | Sell |
-2
| Closed | -$1K | – | 6867 |
|
|
2017
Q4 | $1K | Sell |
2
-37
| -95% | -$17.2K | ﹤0.01% | 6435 |
|
|
2017
Q3 | $18K | Buy |
+39
| New | +$16.7K | ﹤0.01% | 6011 |
|
|
2016
Q1 | – | Sell |
-157
| Closed | -$29K | – | 6702 |
|
|
2015
Q4 | $29K | Buy |
+157
| New | +$26.4K | ﹤0.01% | 5568 |
|
Other funds holding PVLA
SCM
FLAM
BI
FLSM
VCM
Royal Bank of Canada's PVLA Position: Q1 2026 in Review
Royal Bank of Canada reduced its Palvella Therapeutics (PVLA) stake by 94% in Q1 2026, selling an estimated $226K and leaving 128 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #6000.
Royal Bank of Canada first reported a position in PVLA in Q4 2015 and has held it in 24 quarters since. The position peaked at $240K in Q4 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.
- Royal Bank of Canada held 128 shares of Palvella Therapeutics worth $16K as of Q1 2026.
- Royal Bank of Canada sold 2,169 Palvella Therapeutics shares in Q1 2026, an estimated $226K.
- Palvella Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6000 holding.
- Royal Bank of Canada first reported a position in Palvella Therapeutics in Q4 2015 and has held it in 24 quarters since.
- Royal Bank of Canada's Palvella Therapeutics position peaked at $240K in Q4 2025.
- 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.